Fig. 6: AD patient-reported outcomes. | Nature Communications

Fig. 6: AD patient-reported outcomes.

From: The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials

Fig. 6

a DLQI mean % change from baseline ± SEM. b POEM mean % change from baseline ± SEM. c, Proportion with post-baseline DLQI score reduced by ≥ 4 points among patients with baseline score ≥ 4. d Proportion with post-baseline POEM score reduced by ≥ 4 points among patients with baseline score ≥ 4. e Proportion with post-baseline itch NRS scale reduced by ≥ 4 points among patients with baseline score ≥ 4. Red, REZPEG 24 µg/kg; blue, REZPEG 12 µg/kg; grey, placebo. For continuous endpoints using observed data (a and b), number of subjects at each time point shown in Supplementary Table 9. All responder data shown as % of adjusted ITT populations. DLQI, Dermatology Life Quality Index; ITT, intention to treat; NRI, non-responder imputation; NRS, numeric rating scale; POEM Patient-Oriented Eczema Measure; SEM standard error of the mean. Source data are provided as a Source Data file.

Back to article page